XTX Topco’s Context Therapeutics CNTX Stock Holding History

XTX Topco’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-101,605	Closed	-$149K	–	3903
2025 Q4	$149K	Buy	101,605 +91,008	+859%	+$106K	﹤0.01%	2500
2025 Q3	$10.3K	Buy	+10,597	New	+$8.59K	﹤0.01%	2441
2025 Q2	–	Sell	-15,673	Closed	-$9.59K	–	2469
2025 Q1	$9.59K	Buy	+15,673	New	+$13.6K	﹤0.01%	2255
2024 Q2	–	Sell	-10,261	Closed	-$14.2K	–	1957
2024 Q1	$14.2K	Buy	+10,261	New	+$11.5K	﹤0.01%	1642
2023 Q4	–	Sell	-13,259	Closed	-$20K	–	1674
2023 Q3	$20K	Buy	+13,259	New	+$15K	﹤0.01%	1373

Other funds holding CNTX

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

XTX Topco's CNTX Position: Q1 2026 in Review

XTX Topco sold out of Context Therapeutics (CNTX) in Q1 2026, closing a stake of 101,605 shares — an estimated $149K sold.

XTX Topco first reported a position in CNTX in Q3 2023 and held it in 5 quarters. The position peaked at $149K in Q4 2025. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

XTX Topco reported no remaining Context Therapeutics position as of Q1 2026 after selling out during the quarter.
XTX Topco sold 101,605 Context Therapeutics shares in Q1 2026, an estimated $149K.
XTX Topco first reported a position in Context Therapeutics in Q3 2023 and held it in 5 quarters.
XTX Topco's Context Therapeutics position peaked at $149K in Q4 2025.
59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.